6505--Notice of Intent to Sole Source F-18 Piflufolastat (Pylarify for the George E. Wahlen VA Medical Center in Salt Lake City, Utah.
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office 19 (NCO 19), intends to award a sole source task order to Progenics Pharmaceuticals, Inc. for PYLARIFY® (piflufolastat F 18) Injections. This procurement is for the continued provision of unit dose radiopharmaceuticals for Positron Emission Tomography (PET) imaging at the George E. Wahlen VA Medical Center in Salt Lake City, Utah. Interested parties who believe they can meet this requirement must submit their capabilities by February 4, 2026, 3:00 PM MST.
Purpose & Scope
This notice outlines the VA's intent to secure F-18 Piflufolastat (Pylarify) for diagnostic imaging exams and quality assurance procedures within the Nuclear Medicine Department of the VA Salt Lake City Health Care System (VASLCHCS). Pylarify is a radiopharmaceutical containing radioactive isotopes used for diagnosing specific pathologies.
Key Deliverables & Requirements:
- Routine weekday deliveries of radiopharmaceuticals by 8:00 AM MST.
- Supply unit dose syringes of F-18 Piflufolastat (Pylarify) for PET imaging as ordered.
- Provide necessary radiation safety equipment (e.g., syringe shields, shielded carriers).
- Maintain an adequate supply with proof of a contingency supply chain.
- Supply F-18 quality assurance/quality control radioactive sources as needed.
- Ensure deliveries incorporate sufficient shielding and comply with all federal and state regulations for radioactive material shipment.
Contract Details
- Type: Intent to Sole Source (Task Order)
- Intended Awardee: Progenics Pharmaceuticals, Inc.
- Authority: FAR Part 8 – Required Sources of Supplies and Services
- NAICS Code: 325412 Pharmaceutical Preparation Manufacturing (Size Standard: $34 Million)
- PSC: 6505 Drugs and Biologicals
- Period of Performance: Base period plus three (3) option years, commencing Fiscal Year 2026.
- Place of Performance: Nuclear Medicine Service, 500 Foothill Dr., Salt Lake City, UT 84148, room 1E27-1.
Special Requirements
- Contractor must be licensed by the State of Utah and hold current NRC and/or FDA licenses.
- Adherence to U.S. Pharmacopeia (USP) 797 and 825 guidelines.
- Ability to accept returns for credit for specific reasons (e.g., contractor error, damaged goods).
- Provision of current package inserts and Safety Data Sheets (SDS).
- Personnel assigned must be nuclear pharmacists or licensed technologists under supervision.
- Demonstrate proximity to VASLCHCS for timely deliveries (within 60 minutes for stat low energy doses) and potentially have a cyclotron within 2 hours.
- Provide proof of a Dose Management System upon request.
Submission & Response
This is NOT a solicitation or request for offers. No solicitation package is available. Interested parties must clearly demonstrate their capability to meet the Government's need, including relevant information such as specifications, cut sheets, brochures, or capability statements.
- Response Due: Wednesday, February 4th, 2026, by 3:00 PM Mountain Standard Time.
- Submit To: heather.chase2@va.gov
Notes
A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. The Government is not responsible for any potential costs incurred by interested parties responding to this notice.